tiprankstipranks
Agilon Health Inc (AGL)
NYSE:AGL
US Market
Want to see AGL full AI Analyst Report?

Agilon Health (AGL) Stock Forecast & Price Target

378 Followers
See the Price Targets and Ratings of:

AGL Analyst Ratings

Hold
15Ratings
Hold
4 Buy
8 Hold
3 Sell
Based on 15 analysts giving stock ratings to
Agilon
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AGL Stock 12 Month Forecast

Average Price Target

$50.96
▲(69.59% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Agilon Health in the last 3 months. The average price target is $50.96 with a high forecast of $95.00 and a low forecast of $0.50. The average price target represents a 69.59% change from the last price of $30.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","49":"$49","74":"$74","99":"$99","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.96153846153846,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,24,49,74,99],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,34.61230769230769,39.644615384615385,44.676923076923075,49.70923076923077,54.74153846153846,59.77384615384615,64.80615384615385,69.83846153846153,74.87076923076923,79.90307692307692,84.9353846153846,89.9676923076923,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,31.224733727810648,32.8694674556213,34.51420118343195,36.1589349112426,37.80366863905326,39.4484023668639,41.093136094674556,42.73786982248521,44.382603550295855,46.02733727810651,47.67207100591716,49.31680473372781,{"y":50.96153846153846,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,27.34307692307692,25.106153846153845,22.869230769230768,20.63230769230769,18.395384615384614,16.158461538461538,13.92153846153846,11.684615384615384,9.447692307692307,7.21076923076923,4.973846153846154,2.736923076923077,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":98.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.912,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.549,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.217,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.697,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.387,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$95.00Average Price Target$50.96Lowest Price Target$0.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$13$95
Buy
216.14%
Upside
Reiterated
05/21/26
Agilon Health price target raised to $95 from $13 at BenchmarkAgilon Health price target raised to $95 from $13 at Benchmark
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
$67
Hold
122.96%
Upside
Reiterated
05/18/26
Agilon Health (AGL) Gets a Hold from Truist Financial
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$22.04$86
Hold
186.19%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Cardiff Oncology (NASDAQ: CRDF)
Citi
$18.75$80
Hold
166.22%
Upside
Reiterated
05/15/26
Agilon Health price target raised to $80 from $18.75 at CitiAgilon Health price target raised to $80 from $18.75 at Citi
TD Cowen Analyst forecast on AGL
TD Cowen
TD Cowen
$17$55
Hold
83.03%
Upside
Assigned
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Barclays
$0.5
Sell
-98.34%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), CG Oncology, Inc. (NASDAQ: CGON) and Denali Therapeutics (NASDAQ: DNLI)
Deutsche Bank  Analyst forecast on AGL
Deutsche Bank
Deutsche Bank
$33$49
Buy
63.06%
Upside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at Deutsche BankAgilon Health upgraded to Buy from Hold at Deutsche Bank
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$27.5$48
Buy
59.73%
Upside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at JefferiesAgilon Health upgraded to Buy from Hold at Jefferies
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$37.5$72
Buy
139.60%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Argenx Se (NASDAQ: ARGX)
Needham
Hold
Reiterated
05/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL), Lyell Immunopharma (NASDAQ: LYEL) and MacroGenics (NASDAQ: MGNX)
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$20$35
Hold
16.47%
Upside
Reiterated
05/07/26
Agilon Health price target raised to $35 from $20 at BairdAgilon Health price target raised to $35 from $20 at Baird
Evercore ISI
$16$32
Hold
6.49%
Upside
Reiterated
05/07/26
Agilon Health price target raised to $32 from $16 at Evercore ISIAgilon Health price target raised to $32 from $16 at Evercore ISI
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
$6.25$22
Sell
-26.79%
Downside
Reiterated
05/07/26
Agilon Health (AGL) Receives a Sell from Bank of America Securities
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
05/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), US Physical Therapy (NYSE: USPH) and 908 Devices (NASDAQ: MASS)
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
$21
Sell
-30.12%
Downside
Downgraded
05/04/26
Agilon Health downgraded to Underweight from Neutral at JPMorganAgilon Health downgraded to Underweight from Neutral at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Benchmark Co. Analyst forecast on AGL
Benchmark Co.
Benchmark Co.
$13$95
Buy
216.14%
Upside
Reiterated
05/21/26
Agilon Health price target raised to $95 from $13 at BenchmarkAgilon Health price target raised to $95 from $13 at Benchmark
Truist Financial Analyst forecast on AGL
Truist Financial
Truist Financial
$67
Hold
122.96%
Upside
Reiterated
05/18/26
Agilon Health (AGL) Gets a Hold from Truist Financial
Bernstein Analyst forecast on AGL
Bernstein
Bernstein
$22.04$86
Hold
186.19%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Cardiff Oncology (NASDAQ: CRDF)
Citi
$18.75$80
Hold
166.22%
Upside
Reiterated
05/15/26
Agilon Health price target raised to $80 from $18.75 at CitiAgilon Health price target raised to $80 from $18.75 at Citi
TD Cowen Analyst forecast on AGL
TD Cowen
TD Cowen
$17$55
Hold
83.03%
Upside
Assigned
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Barclays
$0.5
Sell
-98.34%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), CG Oncology, Inc. (NASDAQ: CGON) and Denali Therapeutics (NASDAQ: DNLI)
Deutsche Bank  Analyst forecast on AGL
Deutsche Bank
Deutsche Bank
$33$49
Buy
63.06%
Upside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at Deutsche BankAgilon Health upgraded to Buy from Hold at Deutsche Bank
Jefferies Analyst forecast on AGL
Jefferies
Jefferies
$27.5$48
Buy
59.73%
Upside
Upgraded
05/07/26
Agilon Health upgraded to Buy from Hold at JefferiesAgilon Health upgraded to Buy from Hold at Jefferies
Wells Fargo Analyst forecast on AGL
Wells Fargo
Wells Fargo
$37.5$72
Buy
139.60%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL) and Argenx Se (NASDAQ: ARGX)
Needham
Hold
Reiterated
05/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL), Lyell Immunopharma (NASDAQ: LYEL) and MacroGenics (NASDAQ: MGNX)
Robert W. Baird Analyst forecast on AGL
Robert W. Baird
Robert W. Baird
$20$35
Hold
16.47%
Upside
Reiterated
05/07/26
Agilon Health price target raised to $35 from $20 at BairdAgilon Health price target raised to $35 from $20 at Baird
Evercore ISI
$16$32
Hold
6.49%
Upside
Reiterated
05/07/26
Agilon Health price target raised to $32 from $16 at Evercore ISIAgilon Health price target raised to $32 from $16 at Evercore ISI
Bank of America Securities Analyst forecast on AGL
Bank of America Securities
Bank of America Securities
$6.25$22
Sell
-26.79%
Downside
Reiterated
05/07/26
Agilon Health (AGL) Receives a Sell from Bank of America Securities
William Blair Analyst forecast on AGL
William Blair
William Blair
Hold
Reiterated
05/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), US Physical Therapy (NYSE: USPH) and 908 Devices (NASDAQ: MASS)
J.P. Morgan Analyst forecast on AGL
J.P. Morgan
J.P. Morgan
$21
Sell
-30.12%
Downside
Downgraded
05/04/26
Agilon Health downgraded to Underweight from Neutral at JPMorganAgilon Health downgraded to Underweight from Neutral at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilon Health

3 Months
George HillDeutsche Bank
Success Rate
5/11 ratings generated profit
45%
Average Return
-0.65%
Copying George Hill's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -0.65% per trade.
1 Year
Success Rate
6/11 ratings generated profit
55%
Average Return
-127.68%
Copying Andrew Mok CFA's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of -127.68% per trade.
2 Years
Bill SutherlandBenchmark Co.
Success Rate
4/11 ratings generated profit
36%
Average Return
+90.41%
Copying Bill Sutherland's trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +90.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGL Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
0
0
0
0
Buy
0
1
1
2
9
Hold
12
10
14
15
21
Sell
2
1
2
2
2
Strong Sell
0
1
1
1
2
total
15
13
18
20
34
In the current month, AGL has received 9 Buy Ratings, 21 Hold Ratings, and 4 Sell Ratings. AGL average Analyst price target in the past 3 months is 50.96.
Each month's total comprises the sum of three months' worth of ratings.

AGL Financial Forecast

AGL Earnings Forecast

Next quarter’s earnings estimate for AGL is $0.05 with a range of -$0.99 to $0.79. The previous quarter’s EPS was $1.80. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s earnings estimate for AGL is $0.05 with a range of -$0.99 to $0.79. The previous quarter’s EPS was $1.80. AGL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Sales Forecast

Next quarter’s sales forecast for AGL is $1.43B with a range of $1.30B to $1.48B. The previous quarter’s sales results were $1.42B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.
Next quarter’s sales forecast for AGL is $1.43B with a range of $1.30B to $1.48B. The previous quarter’s sales results were $1.42B. AGL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AGL has Performed in-line its overall industry.

AGL Stock Forecast FAQ

What is AGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilon Health Inc’s 12-month average price target is 50.96.
    What is AGL’s upside potential, based on the analysts’ average price target?
    Agilon Health Inc has 69.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AGL a Buy, Sell or Hold?
          Agilon Health Inc has a consensus rating of Hold which is based on 4 buy ratings, 8 hold ratings and 3 sell ratings.
            What is Agilon Health Inc’s price target?
            The average price target for Agilon Health Inc is 50.96. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $95.00 ,the lowest forecast is $0.50. The average price target represents 69.59% Increase from the current price of $30.05.
              What do analysts say about Agilon Health Inc?
              Agilon Health Inc’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.